Edition:
United Kingdom

Novan Inc (NOVN.OQ)

NOVN.OQ on NASDAQ Stock Exchange Global Market

4.36USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$4.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
14,597
52-wk High
$28.69
52-wk Low
$3.52

Latest Key Developments (Source: Significant Developments)

Novan announces first patient dosed in phase 1B Atopic Dermatitis trial With Sb414
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Novan Inc ::NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414.NOVAN INC - ‍ TOP LINE RESULTS FROM PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414​ ARE TARGETED FOR Q3 OF 2018.NOVAN INC - ‍TOP LINE RESULTS ARE TARGETED FOR Q2 OF 2018 FROM PREVIOUSLY ANNOUNCED PHASE 1B CLINICAL TRIAL WITH SB414 FOR TREATMENT OF PSORIASIS​.  Full Article

Novan says ‍agreed to business structure to enable development of SB204 via 3rd party financing and execution
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Novan Inc ::Novan Inc -‍agreed to business structure to enable development of SB204 via 3rd party financing, 3rd party execution of additional Phase 3 pivotal trial​.Novan Inc - ‍proposed Phase 3 trial would be executed by third party's dermatology drug development team​.Novan Inc - a ‍new entity established by third party to provide capital to fund, expertise to execute additional Phase 3 pivotal trial for sb204​.  Full Article

Novan acquires IP rights to treat viral malignancies with nitric oxide
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Novan Inc :Novan acquires IP rights to treat viral malignancies with nitric oxide.Novan Inc- ‍ Has initiated clinical development of company's nitric oxide platform in field of immunology​.Novan Inc- ‍Top line results for phase 1b trial of co's nitric oxide platform​ are expected in Q2 of 2018.Novan Inc- ‍Targeting to begin phase 1b trial with SB414 in adults with atopic dermatitis before year end with top line results expected in Q3 of 2018​.  Full Article

BRIEF-Novan announces first patient dosed in phase 1B Atopic Dermatitis trial With Sb414

* NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414